Clinical trials: Pheochromocytoma/Paraganglioma (PPGL)
Primary Aldosteronism, Adrenal Tumor
Comparative Study of Perioperative Cardiac Injury in Patients With Functional Adrenal Tumors
The main goal of this study is to follow patients with functional adrenal tumors during the time before and after their surgery.
- Conditions
- Primary Aldosteronism, Adrenal Tumor, Cushing s Syndrome, Pheochromocytoma/Paraganglioma (PPGL)
- Trial name
- NCT07182175
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking University First Hospital
Pheochromocytoma and Paraganglioma (PPGL), Adrenocorticol Cancer (ACC)
National Study of Adrenal Tumours
This is a study putting together large numbers of patients with or without a hereditary risk of adrenal tumours including tumours such as adrenocortical carcinoma and phaeochromocytoma/paraganglioma.
- Conditions
- Pheochromocytoma and Paraganglioma (PPGL), Adrenocorticol Cancer (ACC), Adrenal Tumours
- Trial name
- NSAT (NCT06870396)
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Society for Endocrinology
Pheochromocytoma, Paraganglioma
A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL
This phase II trial studies the effectiveness oftemozolomide in the neoadjuvant therapy oflocally advanced,or unresectable pheochromocytoma or paragangliom(PPGL).
- Trial name
- NCT05885386
- Testing
- Temozolomide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Pheochromocytoma, Metastatic, Pheochromocytoma Malignant
The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment
Metastatic pheochromocytoma / paraganglioma (MPP) are rare while the prognosis was poor. Penpulimab is specifically an immune check-point inhibitor of PD1 and has been approved for the treatment of several malignancies.This phase…
- Conditions
- Pheochromocytoma, Metastatic, Pheochromocytoma Malignant, Paraganglioma, Malignant
- Trial name
- NCT05885399
- Testing
- Penpulimab
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Peking Union Medical College Hospital
Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC)
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Background: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types.
- Conditions
- Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC), Mesothelioma, Pheochromocytoma/Paraganglioma (PPGL)
- Trial name
- NCT06503146
- Testing
- [18F]FAPI-74, [18F]FDG
- Where
- United States
- Volunteers
- 320 people
- Sponsor
- National Cancer Institute (NCI)
Risk Grading System, Pheochromocytoma and Paraganglioma (PPGL)
The IUPU-PPGL Score: A Imaging-Based Tool for Stratifying Surgical Complexity in Patients With Pheochromocytoma and Paragangliom（PPGL）
This study aimed to develop the imaging-based IUPU-PPGL score and evaluate its ability to stratify surgical complexity and its association with perioperative outcomes.
- Conditions
- Risk Grading System, Pheochromocytoma and Paraganglioma (PPGL), Quantitative Assessment
- Trial name
- NCT07412158
- Testing
- observational diagnostic model development
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Peking University First Hospital
Pheochromocytomas, Paragangliomas
Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)
This multicenter retrospective Italian study evaluates the efficacy and safety of PRRT in patients with advanced, unresectable or metastatic pheochromocytomas and paragangliomas (PPGL).
- Trial name
- PRRT-PGL-PHEO (NCT07538791)
- Testing
- Peptide Receptor Radionuclide Therapy (PRRT)
- Where
- 10 sites in Italy
- Volunteers
- 210 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Pheochromocytoma/Paraganglioma (PPGL)
Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma
The aim of this study is to evaluate the diagnostic performance of Al18F-NOTA-LM3 PET/CT and compare it with 68Ga-DOTATATE PET/CT in patients with pheochromocytoma/paraganglioma (PPGL).
- Trial name
- NCT07288931
- Testing
- Diagnostic Test: Al18F-NOTA-LM3, Diagnostic Test: 68Ga-DOTATATE
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to <18 years old with somatostatin receptor positive GEP-NETs and PPGLs.
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
- Trial name
- NETTER-P (NCT04711135)
- Testing
- Lutetium [177Lu] oxodotreotide/dotatate
- Where
- 7 sites in United States, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Advanced Accelerator Applications
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated…
- Conditions
- Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor
- Trial name
- NCT04924075
- Testing
- Belzutifan
- Where
- 84 sites in United States, Australia and 20 more
- Volunteers
- 355 people
- Sponsor
- Merck Sharp & Dohme LLC
Pheochromocytoma, Paraganglioma
Correlation Between Preoperative Images of PPGL and Intraoperative Hemodynamics
This is a retrospective observational cohort study involving patients with suspected PPGLs who underwent 131I-MIBG scanning and surgical treatment between January 2020 and April 2023.
- Trial name
- NCT06669481
- Testing
- Semiquantitative 131I-MIBG Scintigraphy Assessment
- Where
- China
- Volunteers
- 159 people
- Sponsor
- Peking Union Medical College Hospital
Pheochromocytoma, Paraganglioma
A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL
This phase II trial studies the effectiveness of anlotinib hydrochloride in the neoadjuvant therapy of locally advanced, or unresectable pheochromocytoma or paragangliom(PPGL).
- Trial name
- NCT05883085
- Testing
- Anlotinib hydrochloride
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Peking Union Medical College Hospital
Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)
First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma
The FIRSTMAPPP study is a randomized, double-blind, phase II, international, multicenter study which aims to determine the efficacy of Sunitinib on the progression-free survival at 12 months in subjects with progressive malignant…
- Trial name
- FIRSTMAPPP (NCT01371201)
- Testing
- Sunitinib
- Where
- 4 sites in France, Germany and 2 more
- Volunteers
- 78 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Pheochromocytoma and Paraganglioma (PPGL), Pheochromocytoma Malignant
An Experimental Study of Belzutifan Impact on Catecholamine Metabolism
To investigate the impact of a medication called Belzutifan on the production and subsequent metabolism of adrenaline and noradrenaline collectively termed 'catecholamines'.
- Conditions
- Pheochromocytoma and Paraganglioma (PPGL), Pheochromocytoma Malignant, Pheochromocytoma, Metastatic, Pheochromocytoma/Paraganglioma
- Trial name
- NCT07680205
- Testing
- Belzutifan
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Pheochromocytoma and Paraganglioma (PPGL)
Safety and Efficacy of Belzutifan in Preoperative Preparation for Patients With Pheochromocytoma/Paraganglioma (PPGL)
It is preliminarily clarified that belzutifan exerts an inhibitory effect on catecholamine synthesis in pheochromocytoma and paraganglioma (PPGL), and its safety is simultaneously confirmed, thereby providing preliminary…
- Trial name
- NCT07907341
- Testing
- Belzutifan
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Longfei Liu，MD
Cushing s Syndrome, Cushing Disease
Adrenal Diseases in the Population of Modena: A Clinical-Epidemiological Database of Patients Referred to the Adrenal Disorders Outpatient Clinic of the Clinical Unit of Endocrinology at the Modena University Hospital (AOU Modena)
Primary Objective: The primary objective of the study is to characterize subjects affected by adrenal disease by collecting medical history data at diagnosis, clinical, bio-humoral, and radiological data, as well as information…
- Conditions
- Cushing s Syndrome, Cushing Disease, Cushing Disease Due to Increased ACTH Secretion, Mild Autonomous Cortisol Secretion (MACS)
- Trial name
- ADRENALINK (NCT07920198)
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Pheochromocytoma, Metastatic, Ultrasonography
Prediction and Evaluation of Anlotinib Treatment Response Using Contrast Enhanced Ultrasound PPGL Patients
Anlotinib is a multi-target receptor tyrosine kinase inhibitor (TKI) targeting tumor angiogenesis and growth. The purpose of this study is to evaluate the efficiency of contrast enhanced ultrasound in assessing effectiveness of…
- Conditions
- Pheochromocytoma, Metastatic, Ultrasonography, Paraganglioma, Malignant, Pheochromocytoma Malignant
- Trial name
- NCT06015061
- Testing
- Contrast-enhanced ultrasound(CEUS)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Adrenocortical Carcinoma, Pheochromocytoma
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
To learn if ivonescimab can help to control previously treated, locally advanced or metastatic ACC or PPGL.
- Conditions
- Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma
- Trial name
- NCT07743138
- Testing
- Ivonescimab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center